Efficacy and Safety of Compound Sophora Flavescens Injection Combined with TCbHP Chemotherapy in the Treatment of HER-2 Positive Breast Cancer
Objective To explore the efficacy and safety of compound sophora flavescens injection combined with TCbHP(docetaxel+carboplatin+trastuzumab+patuzumab)chemotherapy in the treatment of HER-2 positive breast cancer.Methods A total of 102 HER-2 positive breast cancer patients admitted to Second People's Hospital of Xinxiang City from January 2016 to January 2018 were selected and randomly divided into the control group and the study group,with 51 cases in each group.The control group was treated with TCbHP chemotherapy,and the study group was treated with compound matrine injection assisted with TCbHP chemotherapy.Compare the clinical efficacy of the two groups,as well as the QOL-BREF scores,serum tumor markers[carbohydrate antigen 153(CA153),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)]levels,serum carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1),and member of the four-transmembrane protein superfamily 1(TM4SF1)levels before and after 3 cycles of treatment,and compare the 5-year survival rates of the two groups.Results The objective remission rate(ORR)of the study group(62.75%)was higher than that of the control group(43.14%)(P<0.05).After 3 cycles of treatment,the QOL-BREF score of the study group was higher than that of the control group(P<0.05);the levels of serum CA153,CA125,CA199 and CEA in the study group were lower than those in the control group(P<0.05);the serum levels of CEACAM1 and TM4SF1 in the study group were lower than those in the control group(P<0.05).During the treatment period,the incidence of thrombocytopenia,leukopenia,liver function damage,and diarrhea in the study group(13.73%,7.84%,3.92%,5.88%)were lower than those in the control group(31.37%,23.53%,17.65%,21.57%)(P<0.05).The 5-year survival rate of the study group(44.68%)was higher than that of the control group(24.49%)(P<0.05).Conclusion Compound sophora flavescens injection combined with TCbHP chemotherapy can significantly inhibit the progression of HER-2 positive breast cancer patients,prolong the survival period,and improve clinical efficacy and quality of life.
Compound sophora flavescens injectionTCbHPHER-2 positive breast cancerCurative effect
万方数据
维普
